<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">216</article-id><article-id pub-id-type="doi">10.17816/psaic216</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Neurodegeneration with brain iron accumulation</article-title><trans-title-group xml:lang="ru"><trans-title>Наследственные нейродегенерации с накоплением железа в мозге</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rudenskaya</surname><given-names>Galina E.</given-names></name><name xml:lang="ru"><surname>Руденская</surname><given-names>Галина Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>rudenskaya@med-gen.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zakharova</surname><given-names>E. Yu.</given-names></name><name xml:lang="ru"><surname>Захарова</surname><given-names>E. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>rudenskaya@med-gen.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Centre for Medical Genetics</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Медико-генетический научный центр имени Н.П. Бочкова»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-12-09" publication-format="electronic"><day>09</day><month>12</month><year>2013</year></pub-date><volume>7</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>51</fpage><lpage>60</lpage><history><date date-type="received" iso-8601-date="2017-02-02"><day>02</day><month>02</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Rudenskaya G.E., Zakharova E.Y.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, Rudenskaya G.E., Zakharova E.Y.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Rudenskaya G.E., Zakharova E.Y.</copyright-holder><copyright-holder xml:lang="ru">Rudenskaya G.E., Zakharova E.Y.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/216">https://annaly-nevrologii.com/pathID/article/view/216</self-uri><abstract xml:lang="en"><p>Neurodegeneration with brain iron accumulation (NBIA) is a clinically and genetically heterogeneous group of hereditary (predominantly autosomal recessive) progressive disorders of the CNS with a common feature of iron accumulation in basal ganglia and characteristic MRI image. By now, nine genes responsible for different NBIA are known, and some of these genes cause the development of several allelic phenotypes. In the review, current data on NBIA clinical and molecular genetic aspects, particularly on recently discovered forms and atypical clinical variants, are summarized.</p></abstract><trans-abstract xml:lang="ru"><p>Нейродегенерации с накоплением железа в мозге (ННЖМ) – клинически и генетически гетерогенная группа наследственных (преимущественно аутосомно-рецессивных) прогрессирующих болезней ЦНС с общим признаком – накоплением железа в базальных ганглиях, дающим характерную картину при нейровизуализации. В настоящее время идентифицировано 9 генов, связанных с разными ННЖМ, часть из этих генов обусловливают развитие несколько аллельных фенотипов. В обзоре суммированы современные клинические и молекулярно-генетические данные о ННЖМ, особенно о новых формах и атипичных клинических вариантах.</p></trans-abstract><kwd-group xml:lang="en"><kwd>neurodegeneration with brain iron accumulation</kwd><kwd>genetic heterogeneity</kwd><kwd>DNA testing</kwd><kwd>MRI</kwd><kwd>basal ganglia</kwd><kwd>extrapyramidal disorders</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>нейродегенерации с накоплением железа в мозге</kwd><kwd>генетическая гетерогенность</kwd><kwd>ДНК-диагностика</kwd><kwd>МРТ</kwd><kwd>базальные ганглии</kwd><kwd>экстрапирамидные расстройства</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Захарова Е.Ю., Руденская Г.Е. Новая форма наследственной дегенерации с накоплением железа в мозге: клинические и молекулярно-генетические характеристики. Журн. неврол. психиатр. им. С.С.Корсакова (в печати).</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Руденская Г.Е., Захарова Е.Ю., Поляков А.В. Наследственные болезни нервной системы с двигательными расстройствами: «новые» формы, редкие фенотипы, молекулярная диагностика. В кн.: Болезнь Паркинсона и расстройства движений. Рук-во для врачей по материалам II Национального конгресса (под ред. С.Н. Иллариошкина, О.С. Левина). М., 2011: 286–294.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Aggarwal A., Schneider S., Houlden H. et al. Indian-subcontinent NBIA: unusual phenotypes, novel PANK2 mutations, and undetermined genetic forms. Mov. Disord. 2010; 25: 1424–1431.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Alazami A., Al-Saif A., Al-Semari A. et al. Mutations in C2orf37, encoding a nucleolar protein, cause hypogonadism, alopecia, diabetes mellitus, mental retardation, and extrapyramidal syndrome. Am. J. Hum. Genet. 2008; 83: 684–691.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Alazami A., Schneider S., Bonneau D. et al. C2orf37 mutational spectrum in Woodhouse-Sakati syndrome patients. Clin. Genet. 2010; 78: 585–590.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Antonini A., Goldwurm S., Benti R. et al.Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. Mov. Disord. 2006; 21: 417–418.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ben-Omran T., Ali R., Almureikhi M. et al. Phenotypic heterogeneity in Woodhouse-Sakati syndrome: two new families with a mutation in the C2orf37 gene. Am. J. Med. Genet. 2011; 155A: 2647–2653.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bras J., Verloes A., Schneider S. et al. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid lipofuscinosis. Hum. Molec. Genet. 2012; 12: 2646–2650.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Chang M., Hung W., Liao Y. et al. Eye of the tiger-like MRI in</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>parkinsonian variant of multiple system atrophy. J. Neural Transmis. 2009; 116: 861–866.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Chiapparini L., Savoiardo M., D’Arrigo S. et al. The “eye-of-the-tiger” sign may be absent in the early stages of classic pantothenate kinase associated neurodegeneration. Neuropediatrics 2011; 42: 159–162.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Chien H., Bonifani V., Barbosa E. ATP13A2-related neurodegeneration (PARK9) without evidence of brain iron accumulation. Mov. Disord. 2011; 26: 1364–1365.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Ching K., Westaway S., Gitschier J. et al. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 2002; 58: 1673–1674.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Chinnery P. Neuroferritinopathy. GeneReviews. http://www.ncbi.nlm.nih.gov/books/NBK1141.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Chinnery P., CromptonD., Birchall D. et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460insA mutation. Brain 2007; 130: 110–119.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Chung S., Lee J., Lee M. et al. Focal hand dystonia in a patient with PANK2 mutations. Mov. Disord. 2008; 23: 466–468.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Curtis A., Fey C., Morris C. et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 2001; 28:350–354.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>del Valle-López P., Pérez-García R., Sanguino-Andrés R., González-Pablos E. Adult onset Hallervorden-Spatz disease with psychotic symptoms. Actas Esp. Psiquiat. 2011; 39: 260–262.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Deschauer M., Gaul C., Behrmann C. et al. C19orf12 mutations in neurodegeneration with brain iron accumulation mimicking juvenile amyotrophic lateral sclerosis. J. Neurol. 2012; 259: 2434–2439.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Dezfouli M., Alavi A., Rohani M. et al. PANK2 and C19orf12 mutations are common causes of neurodegeneration with brain iron accumulation. Mov. Disord. 2013; 28: 228–232.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Diaz N. Late Onset Atypical Pantothenate-Kinase-Associated Neurodegeneration. Case Rep. Neurol. Med. 2013; 2013: 860201.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Dick K., Al-Mjeni R., Baskir W. et al. A novel locus for an autosomal recessive hereditary spastic paraplegia (SPG35) maps to 16q21-q23. Neurology 2008; 71: 248–252.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Di Fonzo A., Chien H., Socal M. et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 2007; 68: 1557–1562.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Dogu O., Krebs C., Kaleagasi H. et al. Rapid disease progression in adult-onset mitochondrial membrane protein-associated neurodegeneration. Clin. Genet. 2012; Dec 20. doi: 10.1111/cge.12079 [Epub ahead of print].</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Dusek P., Schneider S. Neurodegeneration with brain iron accumulation. Curr. Opin. Neurol. 2012; 25: 499–506.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Edvardson S., Hama H., Shaag A. et al. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am. J. Hum. Genet. 2008; 83: 643–648.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Eiberg H., Hansen L., Korbo L. et al. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Clin. Genet. 2012; 82: 256–263.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Fekete R. Late Onset Neurodegeneration with Brain-Iron Accumulation Presenting as Parkinsonism. Case Rep. Neurol. Med.2012; 387095.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Fong C., Rolfs A., Schwarzbraun T. et al. Juvenile parkinsonism associated with heterozygous frameshift ATP13A2 gene mutation. Eur. J. Paediat. Neurol. 2011; 15: 271–275.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Garone C., Pippucci T., Cordelli D. et al. FA2H-related disorders: a novel c.270+3A&gt;T splice-site mutation leads to a complex neurodegenerative phenotype. Dev. Med. Child Neurol. 2011; 53: 958–961.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Gregory A., Hayflick S. Neurodegeneration with Brain Iron Accumulation Disorders Overview. GeneReviews http://www.ncbi.nlm.nih.gov/books/NBK121988/</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Gregory A., Westaway S., Holm I. et al. Neurodegeneration associated with genetic defects in phospholipase (2). Neurology 2008; 71: 1402–1409.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Gui Y.X., Xu Z.P., Wen-Lu et al. Four novel rare mutations of PLA2G6 in Chinese population with Parkinson’s disease. Parkinsonism Relat. Disord. 2013; 19: 21–26.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Haack T., Hogarth P., Kruer M. et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am. J. Hum. Genet. 2012; 91:1144–1149.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Hartig M., Hörtnagel K., Garavaglia B. et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann. Neurol. 2006; 59: 248–256.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Hartig M., Iuso A., Haack T. et al. Absence of an Orphan Mitochondrial protein, C19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am. J. Hum. Genet. 2011; 89: 543–550.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Hayflick S., Kruer M., Gregory A. et al. Beta-propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain 2013; 136: 1708-1717.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Hider R., Roy S., Ma Y. et al. The potential application of iron chelators for the treatment of neurodegenerative diseases. Metallomic 2011; 3: 239–249.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Hogarth P., Gregory A., Kruer M. et al. New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 2013; 80: 268–275.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Horvath R., Holnski-Feder E., Neeve V. et al. A new phenotype of brain iron accumulation with dystonia, optic atrophy, and peripheral neuropathy. Mov. Disord. 2012; 27: 789–793.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Houlden H., Lincoln S., Farrer M. et al. Compound heterozygous PANK2 mutations confirm HARP and Hallervorden-Spatz syndromes are allelic. Neurology 2003; 61: 1423–1426.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Human Gene Mutation Database (HGMD) http://www.hgmd.cf.ac.uk/ac/</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Keogh M., Chinnery P. Current concepts and controversies in neurodegeneration with brain iron accumulation. Semin. Pediatr. Neurol. 2012; 19: 51–56.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Keogh M., Jonas P., Coulthard A. et al. Neuroferritinopathy: a new inborn error of iron metabolism. Neurogenetics 2012; 13: 93–96.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Kojovic M., Pareés I., Lampreia T. et al. The syndrome of deafnessdystonia:Clinical and genetic heterogeneity. Mov. Disord. 2013; 28:795–803.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Kruer M., Gregory A., Haflick S. Fatty Acid Hydroxylase-Associated Neurodegeneration. GeneReviews http://www.ncbi.nlm.nih.gov/books/NBK56080</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Kruer M., Paisán-Ruiz C., Boddaert N. et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann. Neurol. 2010; 68: 611–618.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Kubota A., Hida A., Ichikawa Y. et al. A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy. Description of clinical features and implications for genotypephenptype correlations. Mov. Disord. 2008; 24: 441–445.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Kumar N., Boes C., Babovic-Vuksanovic D., Boeve B. The “Eye-ofthe-Tiger” sign is not pathognomonic of the PANK2 mutation. Arch. Neurol. 2006; 63: 292–293.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Kurian M., Morgan N., McPherson L. et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008; 70: 623–629.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Lai H., Lin C., Wu R. Early-onset autosomal-recessive parkinsonian-pyramidal syndrome. Acta Neurol. Taiwan 2012; 21: 99–107.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Leoni V., Strittmatter L., Zorzi G. et al. Metabolic consequences of mitochondrial coenzyme A deficiency in patients with PANK2 mutations. Mol. Genet. Metab. 2012; 105: 463–471.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Lin C., Tan E., Chen M. et al. Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore. Neurology 2008; 71:1727–1732.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Lu C., Lai S., Wu R. et al. PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson’s disease. Am. J. Med. Genet. 2012; 159B: 183–191.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Mak C., Sheng B., Lee H. et al. Young-onset parkinsonism in a Hong Kong Chinese man with adult-onset Hallervorden-Spatz syndrome. Int. J. Neurosci. 2011; 121: 224–227.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>McNeill A., Pandolfo M., Kuhn J. et al. The neurological presentation of ceruloplasmin gene mutations. Eur. Neurol. 2008; 60: 200–205.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Morgan N., Westaway S., Morton J. et al. PLA2G6, encoding a phospholipase, A2 is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 2006; 38: 752–754.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Nicholas A., Earnst K., Marson D. Atypical Hallervorden-Spatz disease with preserved cognition and obtrusive obsessions and compulsions. Mov. Disord. 2005; 20: 880–886.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Ogimoto M., Anzai A., Takenoshita H. et al. Criteria for early identification of aceruloplasminemia. Intern. Med. 2011; 50: 1415–1418.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Ohta E. Clinical feature of neuroferritinopathy. Rinsho Shinkeigaku 2012; 52: 951–954.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Ondo W., Adam O., Jankovic J., Chinnery P. Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov. Disord. 2010; 25: 2470–2472.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Oner O., Oner P., Deda G. et al. Psychotic disorder in a case with Hallervorder-Spatz disease. Acta Psychiat. Scand. 2003; 108: 394–397.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>On-line Mendelian Inheritance in Man (OMIM) http://www.ncbi.nlm.nih.gov/omim</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Paisán-Ruiz C., Bhatia K., Li A. et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann. Neurol. 2009; 65:19–23.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Panteghini C., Zorzi G., Venco P. et al. C19orf12 and FA2H mutations are rare in Italian patients with neurodegeneration with brain iron accumulation. Semin. Pediatr. Neurol. 2012; 19: 75–81.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Patil P., Manakshe G., Mahajan D. et al. Neurodegeneration with brain iron accumulation – late-onset slowly progressive variant. J. Assoc. Physicians India 2011; 59: 319–321.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Pellecchia M., Valente E., Cif L. et al. The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology 2005; 64: 1810–1812.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Pierson T., Simeonov D., Sinkan M. et al. Exome sequencing and SNP analysis detect novel compound heterozygosity in fatty acid hydroxylase-associated neurodegeneration. Eur. J. Hum. Genet. 2012;20: 476–479.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Pratini N., Sweeters N., Vichinsky E., Neufeld J. Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen. Am. J. Phys. Med. Rehabil. 2013; Jan 30 [Epub ahead of print].</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Ramirez A., Heimbach A., Grundemann J. et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 2006; 38: 1184–1191.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Saitsu H., Nishimura T., Muramatsu K. et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat. Genet. 2013; 45: 445–449.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Santoro L., Breedveld G., Manganelli F. et al. Novel ATP13A2 (PARK9) homozygous mutations in a family with marked intrafamilial variability. Neurogenetics 2011; 12: 33–39.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Schneider S., Bhatia K. Dystonia in the Woodhouse–Sakati syndrome: A new family and literature review. Mov. Disord. 2008; 23: 592–596.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Schneider S., Bhatia K. Syndromes of neurodegeneration with brain iron accumulation. Semin. Pediatr. Neurol. 2012; 19: 57–66.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Schneider S., Paisan-Ruiz C., Quinn N. et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov. Disord. 2010; 25: 979–984.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Schottmann G., Stenzel W., Lützkendorf S. et al. A novel frameshift mutation of C19ORF12 causes NBIA4 with cerebellar atrophy and manifests with severe peripheral motor axonal neuropathy. Clin. Genet. 2013; Mar 25 [Epub ahead of print].</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Schulte E., Claussen M., Jochim A. et al. Mitochondrial membrane protein associated neurodegeneration: A novel variant of neurodegeneration with brain iron accumulation. Mov. Disord. 2013; 28: 224-227.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Seo J., Song S., Lee P. A Novel PANK2 Mutation in a patient with atypical pantothenate-kinase-associated neurodegeneration presenting with adult-onset parkinsonism. J. Clin. Neurol. 2009; 5: 192–194.</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Shah S., Mehta H., Fekete R. Late-onset neurodegeneration with brain iron accumulation with diffusion tensor magnetic resonance imaging. Case Rep. Neurol. 2012; 4: 216–223.</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Shi C., Tang B., Wang L. et al. PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism. Neurology 2011; 77: 75–81.</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Sina F., Shojaee S., Elahi E., Paisán-Ruiz C. R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family. Eur. J. Neurol. 2009; 16: 101–114.</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Steindl K., Alazami A., Bhatia K. et al. A novel C2orf37 mutation causes the first Italian cases of Woodhouse Sakati syndrome. Clin. Genet. 2010; 78: 594–597.</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Strecker K., Hesse S., Wegner F. et al. Eye of the tiger sign in multiple system atrophy. Eur. J. Neurol. 2007; 14: e1–e2.</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Thomas M., Hayflick S., Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov. Disord. 2004; 19: 36–42.</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Timmermann L., Pauls K., Wieland K. et al. Degeneration with brain iron accumulation. Brain 2010; 133: 701–712.</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Vasconcelos O., Harter D., Duffy C. et al. Adult Hallervorden-Spatz simulating amyotrophic lateral sclerosis. Muscle Nerve 2003; 28:118–122.</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Yoon W., Lee W., Shin H. et al. Novel PANK2 mutations in Korean patient with panthonenate kinase-associated neurodegeneration presenting unilateral dystonic tremor. Mov. Disord. 2010; 25: 245–247.</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Yoshino H., Tomiyama N., Tachibana N. et al. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 2010; 75: 1356–1361.</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Young-Kyung Sunwoo, Jeong-Seop Lee, Won-Hyoung Kim et al. Psychiatric disorder in two siblings with Hallervorden-Spatz disease. Psychiatry Investig. 2009; 6: 226–229.</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Zeidman L., Pandey D. Declining use of the Hallervorden-Spatz disease eponym in the last two decades. J. Child Neurol. 2012; 27: 1310-1315.</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Zorzi G., Zibordi F., Chapparini L., Nardocci N. Therapeutic advances in neurodegeneration with brain iron accumulation. Semin. Pediatr. Neurol. 2012; 19: 82–86.</mixed-citation></ref></ref-list></back></article>
